These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1348 related items for PubMed ID: 30472914

  • 21. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
    Nicolucci A, Candido R, Cucinotta D, Graziano G, Rocca A, Rossi MC, Tuccinardi F, Manicardi V.
    Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
    [Abstract] [Full Text] [Related]

  • 22. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.
    Kaplan A, Abidi E, El-Yazbi A, Eid A, Booz GW, Zouein FA.
    Heart Fail Rev; 2018 May; 23(3):419-437. PubMed ID: 29322280
    [Abstract] [Full Text] [Related]

  • 23. Impact of empagliflozin in patients with diabetes and heart failure.
    Pham D, Albuquerque Rocha N, McGuire DK, Neeland IJ.
    Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
    [Abstract] [Full Text] [Related]

  • 24. SGLT2 inhibitors: a new pillar of the heart failure regimen.
    DeSa T, Gong T.
    Rev Cardiovasc Med; 2021 Dec 22; 22(4):1253-1269. PubMed ID: 34957768
    [Abstract] [Full Text] [Related]

  • 25. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
    Sharma A, Wu J, Ezekowitz JA, Felker GM, Udell JA, Heidenreich PA, Fonarow GC, Mahaffey KW, Hernandez AF, DeVore AD.
    ESC Heart Fail; 2020 Feb 22; 7(1):274-278. PubMed ID: 31747132
    [Abstract] [Full Text] [Related]

  • 26. Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment.
    Oh J, Lee SH, Lee CJ, Kang SM.
    Korean Circ J; 2021 May 22; 51(5):399-408. PubMed ID: 33975387
    [Abstract] [Full Text] [Related]

  • 27. Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential.
    Brito D, Bettencourt P, Carvalho D, Ferreira J, Fontes-Carvalho R, Franco F, Moura B, Silva-Cardoso JC, de Melo RT, Fonseca C.
    Cardiovasc Drugs Ther; 2020 Jun 22; 34(3):419-436. PubMed ID: 32350793
    [Abstract] [Full Text] [Related]

  • 28. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ.
    Circulation; 2016 Sep 06; 134(10):752-72. PubMed ID: 27470878
    [Abstract] [Full Text] [Related]

  • 29. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
    Hwang IC, Cho GY, Yoon YE, Park JJ, Park JB, Lee SP, Kim HK, Kim YJ, Sohn DW.
    Cardiovasc Diabetol; 2020 May 28; 19(1):69. PubMed ID: 32466760
    [Abstract] [Full Text] [Related]

  • 30. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun 28; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 31. [Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV].
    Scheen AJ.
    Rev Med Suisse; 2020 Aug 26; 16(703):1483-1488. PubMed ID: 32852168
    [Abstract] [Full Text] [Related]

  • 32. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG.
    Curr Pharm Des; 2018 Aug 26; 24(17):1879-1886. PubMed ID: 29865997
    [Abstract] [Full Text] [Related]

  • 33. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
    Hofer F, Kazem N, Richter B, Sulzgruber P, Schweitzer R, Pailer U, Hammer A, Koller L, Hengstenberg C, Niessner A.
    Cardiovasc Drugs Ther; 2022 Jun 26; 36(3):497-504. PubMed ID: 34342791
    [Abstract] [Full Text] [Related]

  • 34. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E, Santos-Gallego CG, Diaz-Mejía N, Badimon JJ.
    Cardiovasc Drugs Ther; 2018 Apr 26; 32(2):213-222. PubMed ID: 29679303
    [Abstract] [Full Text] [Related]

  • 35. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N, Wang Y, Tse G, Korantzopoulos P, Letsas KP, Zhang Q, Li G, Lip GYH, Liu T.
    Eur J Prev Cardiol; 2022 Feb 03; 28(17):1961-1973. PubMed ID: 34792124
    [Abstract] [Full Text] [Related]

  • 36. SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
    Pabel S, Hamdani N, Luedde M, Sossalla S.
    Curr Heart Fail Rep; 2021 Oct 03; 18(5):315-328. PubMed ID: 34523061
    [Abstract] [Full Text] [Related]

  • 37. Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland.
    Lymperopoulos A, Borges JI, Cora N, Sizova A.
    Int J Mol Sci; 2021 Jul 19; 22(14):. PubMed ID: 34299304
    [Abstract] [Full Text] [Related]

  • 38. Current Role of Dapagliflozin in Clinical Practice.
    Zargar AH, Trailokya AA, Ghag S, Pawar R, Aiwale A, Zalke A.
    J Assoc Physicians India; 2021 Sep 19; 69(9):11-12. PubMed ID: 34585897
    [Abstract] [Full Text] [Related]

  • 39. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.
    Akiyama H, Nishimura A, Morita N, Yajima T.
    Front Endocrinol (Lausanne); 2023 Sep 19; 14():1111984. PubMed ID: 36793276
    [Abstract] [Full Text] [Related]

  • 40. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
    De Lorenzi AB, Kaplinsky E, Zambrano MR, Chaume LT, Rosas JM.
    Drugs Context; 2023 Sep 19; 12():. PubMed ID: 36660013
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 68.